Archive for 'Risk' Category

Electronic Prescribing

By Anthony - Last updated: Monday, February 6, 2012

Last September the NHS’s flagship IT project was finally allowed to sink into the Davy Jones locker of the last government’s IT failures, after warnings from Private Eye , the BMA, and even contractors associated with it. It cost over £12 billion. Even now, some companies may be sucked into the depths with it. NHS […]

Implants: Some thoughts

By Anthony - Last updated: Friday, December 30, 2011

Not all the fuss about Pip this month concerns Douglas Booth’s performance in Great Expectations. The French government has promised to foot the bill for 30,000 French women to have their breast implants supplied by Poly Implant Prothese (PIP) removed. One investigation has found a higher rupture rate of these implants, and non-authorised silicone gel […]

ISOP 2011

By Anthony - Last updated: Saturday, October 29, 2011

This week I have been at the International Society of Pharmacovigilance‘s 2011 meeting in Istanbul. My colleagues and I have been presenting data on missed doses (adults and children), causality and prevention of adverse drug reactions, the use of rivaroxoban for total knee replacement, and patient internet accounts of serious Stevens Johnson Syndrome and Toxic […]

Xigris Grounded

By Anthony - Last updated: Tuesday, October 25, 2011

Drotrecogin alfa (Xigris) has been withdrawn from the market, because it doesn’t work. It was granted a licence in the full knowledge that insufficient data existed for a standard licence, and was under yearly review by the European Medicines Agency. It was restricted for use in those with severe sepsis and at least two organ […]

Orwell’s adverse drug reaction

By Anthony - Last updated: Monday, May 11, 2009

The Guardian has an interesting piece on Orwell and the writing of 1984. The information about the treatment of Orwell’s tuberculosis (TB) seems to indicate that he suffered a fairly severe skin hypersensivity reaction to streptomycin. “In 1947 there was no cure for TB – doctors prescribed fresh air and a regular diet – but […]

A tragic sledging incident and other risky activities

By Anthony - Last updated: Wednesday, February 4, 2009

It is interesting to speculate whether the decision, made partially on safety grounds, to shut schools in many areas of the UK may have exposed children to more risks. For example, yesterday I went sledging with a group of children, who had a great time hurtling down a hill and tumbling into snow. However, this […]

Long-acting beta agonists in asthma under scrutiny

By Anthony - Last updated: Saturday, December 13, 2008

The Washington Post reports on an FDA decision on long-acting beta agonists (LABAs) in asthma: The risks of two widely used asthma drugs outweigh their benefits for both children and adults, a U.S. Food and Drug Administration advisory panel said Thursday. The health panel targeted GlaxoSmithKline’s Serevent [salmeterol] and Foradil [formoterol], made jointly by Novartis […]

When to weigh the options

By Anthony - Last updated: Saturday, August 30, 2008

Norman Geras discusses a US decision to advise against PSA testing for prostate cancer: I’m in no position to comment on the medical evidence either way. But men who discover they have prostate cancer too late to benefit from curative treatments are unlikely to be convinced by the arguments against screening. Most of them will […]

Seeding trials and missed opportunities

By Anthony - Last updated: Saturday, August 23, 2008

There is an excellent paper at the Archives of Internal Medicine describing a seeding trial. The authors of the paper helpfully provide a useful and concise description of a such a trial: Seeding trials are clinical trials designed by pharmaceutical companies to promote the use of pharmacotherapies that were recently approved or are under review […]